Conmed Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
5.5%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
$4.54next fiscal year
Monitoring Framework
Key Performance Indicators
Organic Constant Currency Revenue Growth Quarterly210.0%Target: 5.0% to 6.5%
Adjusted Diluted Earnings Per Share (EPS) Quarterly0.9Target: $4.30 to $4.45
Full-Year Operating Cash Flow AnnuallyTarget: $145 million to $155 million
Watch Items
- Gastroenterology (GI) Portfolio Divestiture HeadwindsTrigger: Impact on full-year 2026 reported revenueAction: Monitor the acceleration of operational benefits and resource redirection to high-margin platforms (AirSeal, Buffalo Filter, BioBrace).
- Debt Refinancing and Interest Expense HeadwindsTrigger: At least $0.10 EPS headwind in 2026Action: Track the utilization of the new $450 million delayed draw term loan capacity used to refinance the 2.25% convertible notes due 2026.
Research as of 19 Jun 2026